Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19301849 | 0.79 | HTR2A (0.34) | CAMKK2PANK3 | |
| SCHEMBL26081486 | 0.76 | CAMKK2 (0.33) | CAMKK2NQO1PANK3SOS2ALDH1A1 | |
| SCHEMBL13515892 | 0.76 | NQO1 (0.36) | CAMKK2NQO1PANK3SOS2 | |
| SCHEMBL18368362 | 0.76 | EGLN2 (0.37) | KDM5ACAMKK2NQO1PANK3SOS2 | |
| SCHEMBL24141592 | 0.76 | MEN1 (0.41) | NQO1SOS2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL14349193 | 0.75 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL22135837 | 0.74 | CAMKK2 (0.35) | CAMKK2NQO1PANK3SOS2KDM4E | |
| SCHEMBL17033298 | 0.74 | EGLN2 (0.38) | NQO1SOS2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL25738865 | 0.74 | KDM4E (0.40) | NQO1SOS2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL23970899 | 0.73 | PARP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | KDM5A 4713/4885CAMKK2 603/4885NQO1 3867/4885 |
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | KDM5A 3462/4885CAMKK2 1912/4885NQO1 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.